Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 14,125 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 2 Interventional

Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication

NCT00102050
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Disease
Interventions
NM-702 (phosphodiesterase inhibitor)
Drug
Lead sponsor
Nissan Chemical Industries
Industry
Eligibility
50 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
17
States / cities
Long Beach, California • Riverside, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 19, 2006 · Synced Nov 4, 2026, 5:08 AM EST
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

NCT03358290
View directory record Official record
Conditions
Plaque Psoriasis, Skin Diseases
Interventions
JTE-051, Placebo
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Fountain Valley, California • Fremont, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study

NCT04396990
View directory record Official record
Conditions
Refractive Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil

NCT02946125
View directory record Official record
Conditions
Mydriasis
Interventions
MDD-administered EYN-1601, Phenylephrine 2.5% Eyedrop, Phenylephrine 10% Eyedrop
Combination Product · Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Nov 4, 2026, 5:08 AM EST
Recruiting Phase 3 Interventional

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

NCT05219617
View directory record Official record
Conditions
Seizures, Lennox Gastaut Syndrome
Interventions
Carisbamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Palo Alto, California • Jacksonville, Florida • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

NCT04886518
View directory record Official record
Conditions
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions
Pitolisant Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

NCT05735249
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
ARN-75039 oral capsules, Placebo
Drug
Lead sponsor
Arisan Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 4, 2026, 5:08 AM EST
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

NCT07628049
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections+Metapneumovirus
Interventions
RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine, RSV/hMPV_W low dose vaccine, RSV/hMPV_W medium dose vaccine, RSV/hMPV_W high dose vaccine, RSV/hMPV_X low dose vaccine, RSV/hMPV_X medium dose vaccine, RSV/hMPV_X high dose vaccine, hMPV_Y low dose vaccine, hMPV_Y medium dose vaccine, hMPV_Y high dose vaccine, hMPV_Z low dose vaccine, hMPV_Z medium dose vaccine, hMPV_Z high dose vaccine, Control vaccine, Placebo
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
3
States / cities
Stockbridge, Georgia • Lenexa, Kansas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 4, 2026, 5:08 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

NCT03110549
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
TMB-607, Placebo
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal

NCT00669825
View directory record Official record
Conditions
Celiac Disease
Interventions
ALV003, Placebo
Drug
Lead sponsor
Alvine Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2010 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Assess AER-271

NCT03804476
View directory record Official record
Conditions
Stroke, Stroke, Acute, Stroke, Ischemic
Interventions
AER-271, Placebo
Drug
Lead sponsor
Aeromics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

NCT03353350
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
efpeglenatide (SAR439977), placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Glendale, Arizona • Canoga Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Nov 4, 2026, 5:08 AM EST
Terminated Phase 2 Interventional Results available

Study of Varespladib in Patients Hospitalized With Severe COVID-19

NCT04969991
View directory record Official record
Conditions
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Varespladib, Placebo
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Ventura, California • Miami, Florida • Munster, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Nov 4, 2026, 5:08 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Mom Power With High-Adversity Mothers and Children (MPHAMC)

NCT05129397
View directory record Official record
Conditions
Psychopathology
Interventions
Mom Power, Mom Power Informational Mailing
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
3 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Blue Light Therapy of C. Acnes

NCT04300010
View directory record Official record
Conditions
Acne
Interventions
5% Topical Benzoyl Peroxide Gel, Blue Light Therapy
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

NCT02581410
View directory record Official record
Conditions
Herpes Zoster
Interventions
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
32
States / cities
Huntsville, Alabama • Daly City, California • Los Gatos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 3 Interventional Results available

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

NCT05139810
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Scottsdale, Arizona • San Diego, California • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Nov 4, 2026, 5:08 AM EST
Recruiting Not applicable Interventional

Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

NCT06088355
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders, Neurodegeneration
Interventions
HV-PDAE: High Volume Partnered Dance Aerobic Exercise, MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise, MV-WALK: Moderate Volume Walking, HV-WALK: High Volume Walking
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 3 Interventional

Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy

NCT00656578
View directory record Official record
Conditions
Pain
Interventions
4975, Placebo
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Bakersfield, California • Owings Mills, Maryland • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 3 Interventional Results available

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
sparsentan, irbesartan, Dapagliflozin
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Homewood, Alabama • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 2 Interventional

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00978497
View directory record Official record
Conditions
HCV Infection
Interventions
placebo, ANA598, Peginterferon, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • San Clemente, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Nov 4, 2026, 5:08 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02155660
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Montgomery, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Nov 4, 2026, 5:08 AM EST
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents

NCT00825227
View directory record Official record
Conditions
Fatigue, Chemotherapy Side Effects
Interventions
Armodafinil 150 mg/day, Placebo,
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Muscle Shoals, Alabama • Burbank, California • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Nov 4, 2026, 5:08 AM EST
Active, not recruiting Phase 2 Interventional

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

NCT06928142
View directory record Official record
Conditions
Sjogren Disease
Interventions
Sibeprenlimab, Placebo
Biological · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Riverside, California • Tujunga, California • Brandon, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 4, 2026, 5:08 AM EST